PubMed Central (PMC) Search Page
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2008 | 9 |
| 2009 | 12 |
| 2010 | 11 |
| 2011 | 8 |
| 2012 | 12 |
| 2013 | 8 |
| 2014 | 13 |
| 2015 | 11 |
| 2016 | 8 |
| 2017 | 7 |
| 2018 | 13 |
| 2019 | 9 |
| 2020 | 11 |
| 2021 | 4 |
| 2022 | 8 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
-
Publication date
-
-
Publication stage
These filters represent the three primary types of content included in the PMC archive: 1) content published in a scholarly journal 2) peer-reviewed author manuscripts accepted for publication in a journal and 3) preprint versions of articles collected through the NIH Preprint Pilot, made public prior to peer review
-
-
Collections
The PMC Open Access Subset includes journal articles and preprints that are made available under license terms that allow reuse. Historical back issues refers to digitized content from print journals made available in PMC through the Biomedical Journal Digitization Projects.
-
"Expert Rev Anticancer Ther"[Journal]
The embargo is the time during which the publisher retains exclusive rights to distribute articles. Those articles are made freely available on the PMC website after the embargo period has ended. Citations for articles under an embargo period will still display in the PMC results list by default. Choose “Exclude” to prevent embargoed articles from displaying in your results.
-
An evaluation of taletrectinib for the treatment of ROS1+ non-small cell lung cancer.
- Samaeekia R, Arter Z, Nagasaka M.
- Expert Rev Anticancer Ther. Author manuscript. 2026 Jan 18:10.1080/14737140.2026.2615129. doi: 10.1080/14737140.2026.2615129. Online ahead of print.
- PMCID: PMC13075489
Samaeekia R, et al.Expert Rev Anticancer Ther. Author manuscript. 2026.PMCID: PMC13075489 -
Persisting challenges in the early detection of hepatocellular carcinoma.
- Arvind A, Redmon K, Singal AG.
- Expert Rev Anticancer Ther. Author manuscript. 2025 Feb 24:1-12. doi: 10.1080/14737140.2025.2467184. Online ahead of print.
- PMCID: PMC12353231
Arvind A, et al.Expert Rev Anticancer Ther. Author manuscript. 2025.PMCID: PMC12353231 -
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer.
- Jhaveri K, Burris Rd HA, Yap TA, Hamilton E, Rugo HS, Goldman JW, Dann S, Liu F, Wong GY, Krupka H, Shapiro GI.
- Expert Rev Anticancer Ther. Author manuscript. 2021 Sep 1;21(10):1105-1124. doi: 10.1080/14737140.2021.1944109.
- PMCID: PMC12592983
Jhaveri K, et al.Expert Rev Anticancer Ther. Author manuscript. 2021.PMCID: PMC12592983 -
Future investigative directions for novel therapeutic targets in head and neck cancer.
- Nguyen JP, Woerner LC, Johnson DE, Grandis JR.
- Expert Rev Anticancer Ther. Author manuscript. 2024 Oct 16;24(11):1067-1084. doi: 10.1080/14737140.2024.2417038.
- PMCID: PMC11514385
Nguyen JP, et al.Expert Rev Anticancer Ther. Author manuscript. 2024.PMCID: PMC11514385 -
Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment.
- Miller CD, Likasitwatanakul P, Toye E, Hwang JH, Antonarakis ES.
- Expert Rev Anticancer Ther. Author manuscript. 2024 Sep 20;24(11):1085-1100. doi: 10.1080/14737140.2024.2405103.
- PMCID: PMC11499039
Miller CD, et al.Expert Rev Anticancer Ther. Author manuscript. 2024.PMCID: PMC11499039 -
Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer.
- Vyse S, Huang PH.
- Expert Rev Anticancer Ther. 2021 Dec 28;22(1):3-16. doi: 10.1080/14737140.2022.2016397.
- PMCID: PMC11614048
Vyse S, et al.Expert Rev Anticancer Ther. 2021.PMCID: PMC11614048 -
Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity.
- Fahey CC, Gracie TJ, Johnson DB.
- Expert Rev Anticancer Ther. Author manuscript. 2023 May 22;23(7):673-683. doi: 10.1080/14737140.2023.2215435.
- PMCID: PMC10330517
Fahey CC, et al.Expert Rev Anticancer Ther. Author manuscript. 2023.PMCID: PMC10330517 -
Challenges in the combination of radiotherapy and immunotherapy for breast cancer.
- Zhang R, Clark SD, Guo B, Zhang T, Jeansonne D, Jeyaseelan SJ, Francis J, Huang W.
- Expert Rev Anticancer Ther. Author manuscript. 2023 Apr 11;23(4):375-383. doi: 10.1080/14737140.2023.2188196.
- PMCID: PMC10929662
Zhang R, et al.Expert Rev Anticancer Ther. Author manuscript. 2023.PMCID: PMC10929662 -
Emerging treatment options for prostate cancer.
- Atiq M, Chandran E, Karzai F, Madan RA, Aragon-Ching JB.
- Expert Rev Anticancer Ther. Author manuscript. 2023 May 2;23(6):625-631. doi: 10.1080/14737140.2023.2208352.
- PMCID: PMC10718079
Atiq M, et al.Expert Rev Anticancer Ther. Author manuscript. 2023.PMCID: PMC10718079 -
The evolving therapeutic landscape of antibody-drug conjugates in breast cancer.
- Chen N, Michaels E, Howard F, Nanda R.
- Expert Rev Anticancer Ther. Author manuscript. 2022 Nov 21;22(12):1325-1331. doi: 10.1080/14737140.2022.2147510.
- PMCID: PMC9833603
Chen N, et al.Expert Rev Anticancer Ther. Author manuscript. 2022.PMCID: PMC9833603